Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Rockwell Medical (RMTI) over the last 17 years, with Q3 2025 value amounting to -$1.4 million.

  • Rockwell Medical's Cash from Operations fell 13174.27% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year decrease of 16481.48%. This contributed to the annual value of $4.2 million for FY2024, which is 14464.51% up from last year.
  • As of Q3 2025, Rockwell Medical's Cash from Operations stood at -$1.4 million, which was down 13174.27% from $1.9 million recorded in Q2 2025.
  • Rockwell Medical's 5-year Cash from Operations high stood at $4.3 million for Q3 2024, and its period low was -$12.5 million during Q1 2021.
  • Over the past 5 years, Rockwell Medical's median Cash from Operations value was -$2.4 million (recorded in 2024), while the average stood at -$3.1 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 24056.26% in 2023, then surged by 211162.79% in 2024.
  • Quarter analysis of 5 years shows Rockwell Medical's Cash from Operations stood at -$9.0 million in 2021, then skyrocketed by 98.76% to -$112000.0 in 2022, then surged by 61.61% to -$43000.0 in 2023, then skyrocketed by 2111.63% to $865000.0 in 2024, then tumbled by 256.88% to -$1.4 million in 2025.
  • Its Cash from Operations was -$1.4 million in Q3 2025, compared to $1.9 million in Q2 2025 and -$3.5 million in Q1 2025.